drugset / Trial / NCT06794957
A Study of AL8326 in Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This trial is a multicenter, single arm, open, phase IB clinical trial, designed to evaluate the preliminary efficacy and safety of AL8326 in patients with non-small cell lung cancer (NSCLC) who relapsed or progressed after multi line treatment and failed standard treatment.
Timeline
- Start
- 2022-05-19
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AL8326 | Unknown | 40 mg | Oral |
| Subject | AL8326 | Unknown | 60 mg | Oral |